Sign in
RIGL Stock Price, Chart, Stats & News
Rigel Pharmaceuticals, Inc.
Save
553.77M
Market cap
1.55x
Current P/E
6.74x
Forward P/E
RIGL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 93.33% |
Operating margin | 42.63% |
Pretax margin | 41.40% |
Net margin | 124.72% |
Effective tax rate | -201.27% |
ROA | 71.46% |
ROE | 240.83% |
D/E | 0.14x |
Interest coverage ratio | 17.14x |
RIGL valuation
P/E | 1.55x |
P/S | 1.62x |
P/B | 1.19x |
P/CF | 6.14x |
P/FCF | 6.30x |
P/OCF | 6.14x |
PEG | 0.01x |
EV multiple | 3.63x |
About
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19.
Similar securities
Based on sector and market capitalization
Report issue